Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer
Journal
Cancer medicine
Journal Volume
13
Journal Volume
13
Journal Issue
1
Journal Issue
1
Start Page
e6870
Date Issued
2024
Author(s)
Hsu, Wei-Hsun
Wu, Chia-Ling
Abstract
According to current International Association for the Study of Lung Cancer guideline, physicians may first use plasma cell-free DNA (cfDNA) methods to identify epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant mechanisms (liquid rebiopsy) for lung cancer. Tissue rebiopsy is recommended if the plasma result is negative. However, this approach has not been evaluated prospectively using next-generation sequencing (NGS).
Subjects
EGFR mutation; EGFR-TKI resistance; NSCLC; next-generation sequencing
SDGs
Type
journal article